[1]刘　晟,周平盛,沈　强,等.超声引导下微波消融术治疗特殊部位与非特殊部位单发肝细胞癌的疗效对比[J].介入放射学杂志,2023,32(01):36-42.
　LIU Sheng,ZHOU Pingsheng,SHEN Qiang,et al.Ultrasound-guided microwave ablation for the treatment of single hepatocellular carcinoma located at specific area and at non-specific area: comparison of clinical efficacy[J].journal interventional radiology,2023,32(01):36-42.
点击复制

超声引导下微波消融术治疗特殊部位与非特殊部位单发肝细胞癌的疗效对比()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
32
期数:
2023年01
页码:
36-42
栏目:
非血管介入
出版日期:
2023-02-13

文章信息/Info

Title:
Ultrasound-guided microwave ablation for the treatment of single hepatocellular carcinoma located at specific area and at non-specific area: comparison of clinical efficacy
作者:
刘　晟; 　周平盛; 　沈　强; 　钱国军
Author(s):
LIU Sheng;  ZHOU Pingsheng;  SHEN Qiang;  QIAN Guojun.
Department of Ultrasonic Intervention, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai 200438, China
关键词:
【关键词】肝细胞癌; 特殊部位; 总体生存率; 局部肿瘤进展
文献标志码:
A
摘要:
【摘要】　目的　探讨超声引导下微波消融（microwave ablation，MWA）治疗位于特殊部位单发肝细胞癌（hepatocellular carcinoma，HCC）的安全性、近期及远期疗效。方法　回顾性分析2016年1月至2016年8月在上海东方肝胆外科医院接受MWA治疗的129例HCC患者的临床资料。观察组44例患者的肿瘤位于特殊部位，对照组85例患者的肿瘤位于非特殊部位。收集患者术前一般资料、肿瘤部位、肿瘤大小、随访资料，比较两组患者总体生存率和无瘤生存率。Cox回归分析MWA治疗单发HCC无瘤生存的影响因素。结果　观察组1、2、3、4、5年总体生存率分别为93.2%、86.4%、77.3%、65.9%、61.4%，对照组分别为96.5%、88.2%、82.4%、70.6%、64.7%，差异无统计学意义（P=0.910）。肿瘤直径≤20 mm（HR=0.412，95%CI：0.196～0.867，P=0.020）是MWA治疗单发HCC总体生存的影响因素。观察组1、2、3、4、5年无瘤生存率分别为59.1%、40.9%、29.5%、18.2%、18.2%，对照组分别为77.6%、57.6%、43.5%、35.0%、31.4%，差异有统计学意义（P=0.021）。肿瘤直径≤20 mm（HR=0.447，95%CI：0.278～0.719，P=0.001）和肿瘤位于特殊部位（HR=1.558，95%CI：1.023～2.371，P=0.039）是MWA治疗单发HCC无瘤生存的影响因素。结论　MWA治疗特殊部位单发HCC安全有效，患者总体生存率与非特殊部位HCC相当。

参考文献/References:

［1］　Xie DY, Ren ZG, Zhou J, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights［J］. Hepatobiliary Surg Nutr, 2020, 9: 452-463.
［2］　Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma［J］. Hepatology, 2018, 67: 358-380.
［3］　Liu W, Yang Z, Zou R, et al. Resection vs ablation for multifocal hepatocellular carcinomas meeting the barcelona-clinic liver cancer a classification: a propensity score matching study［J］. J Cancer, 2019, 10: 2857-2867.
［4］ Goldberg SN, Grassi CJ, Cardella JF, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria［J］. Radiology, 2005,235:728-739.
［5］　Teratani T, Yoshida H, Shiina S, et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations［J］. Hepatology, 2010, 43: 1101-1108.
［6］　中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范（2019年版）［J］. 临床肝胆病杂志，2020，36：277-292．
［7］ Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey［J］. Ann Surg, 2004, 240: 205-213.
［8］ Wang XD, Sofocleous CT, Erinjeri JP, et al. Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases［J］. Cardiovasc Intervent Radiol, 2013, 36: 166-175.
［9］王竞立，赵　辉. 消融术治疗高危部位肝癌相关技术研究进展［J］. 介入放射学杂志，2020，29：431-434.
［10］ Qiao Q, Li H, Wu J, et al. Radiofrequency ablation and microwave ablation under artificial ascites for hepatocellular carcinoma adjacent to vital organs［J］. Chinese J Minimally Invasive Surg, 2016: 724-727.
［11］王延明，钱国军，许　赘，等. 微波消融治疗696例米兰标准内肝细胞癌的疗效分析［J］. 中华肝脏病杂志，2017，25：344-348.
［12］ Liu W, Zou R, Wang C, et al. Microwave ablation versus resection for hepatocellular carcinoma within the Milan criteria: a propensity-score analysis［J］. Ther Adv Med Oncol, 2019,11:1758835919874652.
［13］ Yuan BH, Zhu YK, Zou XM, et al. Repeat hepatic resection versus percutaneous ablation for the treatment of recurrent hepatocellular carcinoma: meta-analysis［J］. BJS Open，2022，6:zrac036.
［14］ Wang W, Hou S, Zhong Z, et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization therapy versus surgical resection for Barcelona-Clinic Liver Cancer（BCLC） A hepatocellular carcinoma: a meta-analysis［J］. J Interv Med, 2018, 1: 49-57.
［15］ Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma［J］. J Hepatol, 2009, 51: 890-897.
［16］ Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma［J］. Liver Transpl, 2010, 11: 1086-1092.
［17］ Rui C, Jie Y, Ping L. Microwave ablation versus other interventions for hepatocellular carcinoma: a systematic review and meta- analysis［J］. J Cancer Res Ther, 2020, 16: 379.
［18］沈　强，王　能，张敬磊，等. 超声引导下微波消融治疗肝细胞肝癌的短期预后及影响因素分析［J］. 第二军医大学学报，2021，42：6．
［19］ Xu Y, Shen Q, Liu P, et al. Microwave ablation for the treatment of hepatocellular carcinoma that met up-to-seven criteria: feasibility, local efficacy and long-term outcomes［J］. Eur Radiol, 2017, 27: 3877-3887.
［20］ Lu XY, Xi T, Lau WY, et al. Pathobiological features of small hepatocellular carcinoma: correlation between tumor size and biological behavior［J］. J Cancer Res Clin Oncol, 2011, 137: 567-575.

相似文献/References:

[1]王有枝,李彦豪,梅雀林,等.原发性肝癌肝动脉化疗栓塞术后继发溶血性尿毒综合征3例并文献复习[J].介入放射学杂志,2016,(06):543.
　WANG You-zhi,LI Yan-hao,MEI Que-lin,et al.Secondary hemolytic uremic syndrome occurring after transcatheter arterial chemoembolization for primary hepatocellular carcinoma: report of 3 cases with literature review [J].journal interventional radiology,2016,(01):543.
[2]蒋健强,李晓娟,李拥军,等.白蛋白-胆红素评分在预测TACE治疗巨块型肝细胞癌后肝功能衰竭中的应用[J].介入放射学杂志,2023,32(01):55.
　JIANG Jianqiang,LI Xiaojuan,LI Yongjun,et al.The application of albumin-bilirubin score in predicting liver failure after transarterial chemoembolization for massive hepatocellular carcinoma [J].journal interventional radiology,2023,32(01):55.
[3]王　曦,冯　苏,李　红,等.免疫检查点抑制剂联合TACE在肝癌治疗中的研究进展[J].介入放射学杂志,2023,32(01):90.
　WANG Xi,FENG Su,LI Hong,et al.Research progress in immune checkpoint inhibitors combined with TACE for the treatment of hepatocellular carcinoma[J].journal interventional radiology,2023,32(01):90.
[4]吴迪,郑琳.载药微球栓塞治疗在肝癌全程管理中的临床应用进展[J].介入放射学杂志,2024,33(08):921.
　WU Di,ZHENG Lin..Application progress of drug-loaded microspheres embolization therapy in the clinical full-process management of hepatocellular carcinoma[J].journal interventional radiology,2024,33(01):921.
[5]陈荔,吴大广,朱光宇,等.经动脉化疗栓塞联合免疫和靶向药治疗Child-Pugh B级肝细胞癌研究[J].介入放射学杂志,2024,33(09):968.
　CHEN Li,WU Daguang,ZHU Guangyu,et al.Transarterial chemoembolization combined with immune checkpoint inhibitor and molecular targeted therapy for Child-Pugh grade B hepatocellular carcinoma[J].journal interventional radiology,2024,33(01):968.
[6]石佳鹏,汤小星,顾祝新,等.TACE联合瑞戈非尼及PD-1二线序贯治疗中晚期肝细胞癌的临床研究[J].介入放射学杂志,2024,33(09):995.
　SHI Jiapeng,TANG Xiaoxing,GU Zhuxin,et al.TACE combined with regorafenib and PD-1 second-line sequential therapy for advanced hepatocellular carcinoma：a clinical study[J].journal interventional radiology,2024,33(01):995.
[7]张岩基,王汇源,李浩,等.经导管动脉化疗栓塞和肝动脉灌注化疗治疗肝细胞癌现状和进展[J].介入放射学杂志,2024,33(09):1039.
　ZHANG Yanji,WANG Huiyuan,LI Hao,et al.Current status and progress of TACE and HAIC in the treatment of hepatocellular carcinoma[J].journal interventional radiology,2024,33(01):1039.
[8]殷梦杰,付守忠,戴锋,等.肝动脉灌注化疗联合卡瑞利珠单抗及索拉非尼治疗中晚期肝癌的疗效与安全性分析 [J].介入放射学杂志,2024,33(11):1212.
　YIN Mengjie,FU Shouzhong,DAI Feng,et al.Hepatic arterial infusion chemotherapy combined with carrelizumab and sorafenib for the treatment of advanced hepatocellular carcinoma：its clinical efficacy and safety[J].journal interventional radiology,2024,33(01):1212.
[9]杜楠,王英,李文涛.肝癌TACE还是HAIC？[J].介入放射学杂志,2024,33(12):1269.
　DU Nan,WANG Ying,LI Wentao..Treatment of hepatocellular carcinoma：TACE or HAIC？[J].journal interventional radiology,2024,33(01):1269.
[10]张赛锋,王道仁,邵国良.小粒径载药微球在肝细胞癌治疗中的安全性和疗效分析[J].介入放射学杂志,2024,33(12):1373.
　ZHANG Saifeng,WANG Daoren,SHAO Guoliang..Small-size drug-eluting beads TACE for the treatment of hepatocellular carcinoma：its safety and efficacy analysis[J].journal interventional radiology,2024,33(01):1373.

备注/Memo

备注/Memo:
（收稿日期：2022-08-22）
（本文编辑：新宇）　　
更新日期/Last Update: 2023-02-13